Chronos Archive seal

Review checklist: Duke Kahanamoku (HR-ML050)

All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments

Everything a reviewer needs to judge, gathered from the record. Release status: draft.

Review status

ReviewStatusReviewerDateNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review; check the 36-hour washout from lisinopril to sacubitril-valsartan, the change from metoprolol tartrate to carvedilol, the order of titration, spironolactone with an eGFR above 30 and potassium below 5.0, the sick-day holds when potassium reached 5.5, the missed laboratory check after the last dose increases, intravenous iron at a ferritin of 62, angiography without revascularization, the decision against an ICD at an ejection fraction of 38%, and the ocean-safety plan.
provenance reviewnot_startedSources: PBS American Masters, two Honolulu Star-Advertiser articles of 2018, Olympedia, EBSCO, the International Swimming Hall of Fame and the Encyclopedia of World Biography. The Hawaiʻi State Archives, the Bishop Museum, olympics.com, the New York Times obituary and David Davis's biography Waterman were not read; a 1962 wire report found through Papers Past could not be fetched. The heart attack is dated 1952, not 1955.
safe messaging reviewnot_startedHis Native Hawaiian identity is described as he would describe it, without stereotype; his own healing practices are respected and not described. Mood screening is synthetic and negative. His wife appears only in a documented claim, and no relative or other real person is given a modern statement, decision or health fact.

Judgment calls (dossier editorial resolutions)

  1. Sources. The case relies on PBS American Masters, two Honolulu Star-Advertiser articles of 2018, Olympedia, EBSCO, the International Swimming Hall of Fame and the Encyclopedia of World Biography. The Hawaiʻi State Archives, the Bishop Museum, olympics.com (the athlete page timed out), the New York Times obituary and the 1968 Star-Bulletin and Advertiser obituaries were not read; David Davis's biography Waterman was not read and is not cited. A 1962 wire report on Papers Past of an operation “for a blood clot on the brain at Kaiser Hospital,” seen in a search result, could not be fetched and is not cited. Wikipedia and popular sites were not used.
  2. Recent-death rule. He died in 1968, so the rule does not apply. A sick visit is included.
  3. Heart attack date (correction to the brief). The brief cited a heart attack in 1955. No source read gives 1955; the Star-Advertiser gives 1952, and EBSCO says he had several heart attacks without dates. The record uses 1952 (CLM-0009, certainty “probable”).
  4. Brain operation (correction to the brief). The brief mentioned surgery for a brain blood clot or tumor in about 1962. The Star-Advertiser records a cerebral blood clot in 1962 and EBSCO a brain operation; no source read mentions a tumor. It is recorded as later history (CLM-0010) and not used in the modern episode.
  5. Index age and dates. The index visit on March 16, 2026 maps to March 16, 1957, when he was 66 and sheriff of Honolulu, five years after the 1952 heart attack and five years before the 1962 operation. The synthetic date of birth is 1959-08-24, a shift of 69 years. The visits on March 30, April 13, April 22, April 27, September 14 and September 28, 2026 map to the same days of 1957; he turns 67 before the last two. The medicines begun after the modern heart attack are dated June 21, 2021 (mapping to 1952; the month of the real heart attack is not known). His travel in 1957 is not documented in the sources read; nothing places a visit in conflict with a documented event. The presenting pattern is breathlessness, ankle swelling and tiredness years after a heart attack, resolved into HFrEF at the second visit.
  6. Name and alias. The display name splits simply into given and family names, so identity.name_parts is not used. The alias is Olympedia's full name, Duke Paoa Kahino Makoe Hulikohoa Kahanamoku, which appears in no other record; the brief's spelling (Kahinu Mokoe Hulikohola) and the shorter form Duke Paoa Kahanamoku were not found in a source that could be fetched. “Duke” alone is not an alias. The notes call him Mr. Kahanamoku, as the modern episode records that he asked.
  7. Conflicts recorded. His years as sheriff are 1934 to 1960 in PBS and the Star-Advertiser and 1932 to 1961 in Olympedia, the Encyclopedia of World Biography and EBSCO; either way he was sheriff in 1957. One International Swimming Hall of Fame tribute implies an August 14 birthday by its arithmetic; the dated sources give August 24.
  8. Living people and relatives. His wife appears only in a documented claim (CLM-0007) and is given no role, statement or health fact. His ʻohana in the modern episode, his health care agent and the friend he swims with are synthetic and unnamed. Princess Bernice Pauahi Bishop appears only in the birth claim. No relative or historical person is given a modern statement, decision or health fact.
  9. Culturally safe care. The record follows the approach of the dataset's earlier record of a Native Hawaiian patient: his ʻohana is involved as he chooses and he makes the decisions; lomilomi through Ke Ola Mamo, a real Native Hawaiian Health Care System that lists it among its services, is offered alongside clinic care; no practice or ceremony is described, and the clinic asks nothing further. He is asked to tell the clinic before using any plant medicine so interactions can be checked. His diet is described in his own words, without claiming anything about Native Hawaiian diets in general. The equity point cites the Hawaiʻi study of preventable heart failure hospitalizations; the record quotes no rate beyond that study's findings.
  10. Diagnosis decisions. HFrEF from ischemic cardiomyopathy (I50.22) is recorded at the second visit: NT-proBNP 2,450 pg/mL and an ejection fraction of 30% with a thinned, akinetic anterior wall and apex. The old myocardial infarction (I25.2) is linked to the 1952 heart attack (placement both_with_link); nothing in the record says he had heart failure in his lifetime. Iron deficiency without anemia (E61.1) was found at intake. The intake documents show only what was known at intake.
  11. Treatment choices. (1) Lisinopril stopped and sacubitril-valsartan started 36 hours later; the medication start is dated the consultation day, with the washout in its instructions. (2) Metoprolol tartrate replaced by carvedilol, an evidence-based beta-blocker. (3) Empagliflozin with sick-day rules. (4) Spironolactone 12.5 mg at the third visit, with potassium 4.5 mmol/L and eGFR 69. (5) Intravenous ferric carboxymaltose 750 mg twice for ferritin 62 ng/mL. (6) Coronary angiography showed a chronic total occlusion of the left anterior descending artery feeding a thinned scar, with mild disease elsewhere: no revascularization; no viability imaging was done, a judgment the owner may review. (7) Atorvastatin 80 mg; LDL 92 to 62 mg/dL. (8) Furosemide reduced from 40 to 20 mg once dry. (9) Sodium guidance without routine fluid restriction.
  12. Defibrillator decision. The ejection fraction rose from 30% to 38% after more than five months on all four classes, above the 35% threshold, so a primary-prevention ICD was not indicated; QRS 104 ms, so no CRT. The record notes that sacubitril-valsartan stayed at its starting dose for most of that time and says what would change the decision. His wish to discuss any device with his ʻohana is recorded in his advance care planning.
  13. Ocean safety. Cardiac rehabilitation for heart failure began six weeks after angiography and the last new medicine, as CMS NCD 20.10.1 requires, with supervised pool swimming, then calm water inside the reef with a companion and near a lifeguard, no breath-hold diving and no big surf until cleared. This adapts general exercise guidance to his life; no guideline gives ocean-specific rules.
  14. Synthetic clinical picture. Everything in the modern episode is synthetic: symptoms, the heart attack five years before intake, every blood pressure, all laboratory values, the ECGs, the chest X-ray, the echocardiograms, the angiogram, scores (PHQ-2, KCCQ-12, Mini-Cog, AUDIT-C), medicines and outcomes. Height (185 cm) and weights are synthetic. Reference ranges are typical adult male ranges; the ferritin range notes the heart failure threshold.
  15. Sick visit. Viral gastroenteritis (A08.4) with volume depletion, potassium 5.5 mmol/L and creatinine 1.52 mg/dL nine days after spironolactone, chosen because it follows from four medicines that act on the kidney and insinuates no undocumented diagnosis; the ECG showed no hyperkalemic changes, and sick-day holds brought potassium to 4.8 mmol/L five days later. It is not a historical claim.
  16. Annual wellness visit. A subsequent annual wellness visit at 67 (HCPCS G0439 and CPT 99497 in plain text); the record says his first was with his previous physician (synthetic). Judgment calls: high-dose influenza, RSV (heart failure, age 60 to 74) and COVID-19 that day, with zoster and Tdap at the next visit; FIT for colorectal screening; PSA declined after shared decision-making; no aneurysm screening as a never smoker; hepatitis C once; advance care planning with an unnamed member of his ʻohana as agent, recording that his own Hawaiian practices are to be respected without describing them.
  17. Focused visits. The four chronic-care follow-ups (two weeks with the consultation, two weeks after the first three GDMT medicines, two weeks after spironolactone and five days after the sick visit, and six months) are documented as focused visits on the CMID heart failure and ischemic heart disease monographs, the 2022 heart failure guideline and the 2024 HFrEF decision pathway. One deviation is recorded instead of an invented result: the sacubitril-valsartan increase planned two weeks after the fourth visit, and the metabolic panel due a week after it, never happened, because he put off the laboratory visit twice for work and the nurse's call was not repeated. No laboratory harm resulted (potassium 4.6 mmol/L and creatinine 1.14 mg/dL at six months), but the ARNI stayed at its starting dose for about five months, which may have limited his recovery. The corrective action was laboratory tests drawn at the clinic on the day of each change or by the nurse at home, with nurse calls continuing until each step is done. The one-to-two-week check after spironolactone was covered by the sick-visit panel at nine days and the fourth-visit panel at two weeks. Synthetic findings introduced: iron deficiency, the angiogram, the hyperkalemia during gastroenteritis, the KCCQ-12 rising from 38 to 80, and the ejection fraction rising to 38%.
  18. Consultation. The heart failure referral and the consultation by Noelani Abernathy-Chen, MD (a fictional consultant), on the day of the two-week visit, are S. The consultant answers the six referral questions in line with what the record shows afterwards: HFrEF from ischemic cardiomyopathy; angiography within two weeks; all four classes started within weeks in the stated order and titrated with laboratory checks; intravenous iron twice; a repeat echocardiogram after 90 days of therapy before any ICD decision, and no CRT with a QRS of 104 ms; and cardiac rehabilitation, then a graded return to the ocean.

Protocol deviations

Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.

VisitMeasureIntervalWhat happened
2026-09-28
Progress note 07 (C-CDA)
Metabolic panel (sodium, potassium, creatinine and eGFR) and magnesiumOne to two weeks after a dose changeThe panel due one week after the planned sacubitril-valsartan increase was never drawn, because the increase itself did not happen: he put off the laboratory visit twice for work and the nurse's call was not repeated. No laboratory harm resulted (potassium 4.6, creatinine 1.14 today), but the ARNI stayed at the starting dose for about five months, which may have limited his recovery. Corrective action: laboratory tests drawn at the clinic on the day of each change or by the nurse at home, and nurse calls that continue until each step is done

Orders and referrals without results in the record

VisitTypeItemStatusDetail
2026-03-30
Progress note 02 (C-CDA)
LaboratoryLipid panelOrderedLDL 92 mg/dL at intake; atorvastatin raised to 80 mg; panel due four to twelve weeks after the change
2026-04-27
Progress note 05 (C-CDA)
ReferralCardiac rehabilitation for heart failureOrderedProgram booked from late May, when he becomes eligible
2026-09-14
Progress note 06 (C-CDA)
PreventionColorectal cancer screeningOrderedAge 45 to 75; no screening on record; a stool immunochemical (FIT) kit given today
2026-09-14
Progress note 06 (C-CDA)
PreventionHepatitis C screeningOrderedOne-time screening for adults 18 to 79; never tested

Evidence to check

Retrospective claims (R)

None.

Sensitive claims

None.

Diagnoses not confirmed

None.

Notes to read

Every note in the record, with its type. All clinical content is synthetic.

Abnormal results

DateResultValueFlag
2026-03-16NT-proBNP2450 pg/mL (high)High
2026-03-16Glucose102 mg/dL (high)High
2026-03-16Ferritin62 ng/mL (low)Low
2026-03-16Transferrin saturation16% (low)Low
2026-03-16Hemoglobin A1c5.9% (high)High
2026-03-16LDL cholesterol92 mg/dL (high)High
2026-03-16Triglycerides160 mg/dL (high)High
2026-03-30LVEF by echocardiogram30% (low)Low
2026-04-22Sodium133 mmol/L (low)Low
2026-04-22Potassium5.5 mmol/L (high)High
2026-04-22Creatinine1.52 mg/dL (high)High
2026-04-22eGFR (CKD-EPI 2021)50 mL/min/1.73 m² (low)Low
2026-09-28NT-proBNP620 pg/mL (high)High
2026-09-28LVEF by echocardiogram38% (low)Low